Ana Vizcaíno

Mrs. Ana Vizcaíno

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MGMarcela Guevara
Marcela Guevara
AMAmaia Molinuevo
Amaia Molinuevo
DSDiego Salmerón
Diego Salmerón
Rafael Marcos-GrageraRafael Marcos-Gragera
Rafael Marcos-Gragera
MCMarià Carulla
Marià Carulla
EAEva Ardanaz
Eva Ardanaz
The assessment of cancer survival at the population level is essential for monitoring progress in cancer control. We aimed to assess cancer survival and its trends in adults in Spain. Individual records of 601,250 adults with primary cancer diagnosed during 2002–2013 and followed up to 2015 were included from 13 population-based cancer registries. We estimated net survival up to five years after diagnosis and analyzed absolute changes between 2002–2007 and 2008–2013. Estimates were age-standardized. Analyses were performed for 29 cancer groups, by age and sex. Overall, age-standardized five-year net survival was higher in women (61.7%, 95% CI 61.4–62.1%) than in men (55.3%, 95% CI 55.0–55.6%), and ranged by cancer from 7.2% (pancreas) to 89.6% (prostate) in men, and from 10.0% (pancreas) to 93.1% (thyroid) in women in the last period. Survival declined with age, showing different patterns by cancer. Between both periods, age-standardized five-year net survival increased overall by 3.3% (95% CI 3.0–3.7%) in men and 2.5% (95% CI 2.0–3.0%) in women, and for most cancer groups. Improvements were greater in patients younger than 75 years than in older patients. Chronic myeloid leukemia and myeloma showed the largest increases. Among the most common malignancies, the greatest absolute increases in survival were observed for colon (5.0%, 95% CI 4.0–6.0%) and rectal cancers (4.5%, 95% CI 3.2–5.9%). Survival improved even for some cancers with poor prognosis (pancreas, esophagus, lung, liver, and brain cancer). Further investigation of possible sociodemographic inequalities is warranted. This study contributes to the evaluation of cancer control and health services’ effectiveness.

1 November 2020 in Allergologia et Immunopathologia
Verified
Journal Article
Closed access
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
AAA. Artero-Civera
A. Artero-Civera
MRM.A. Romeu-Garcia
M.A. Romeu-Garcia
NMN. Meseguer-Ferrer
N. Meseguer-Ferrer
JBJ.B. Bellido-Blasco
J.B. Bellido-Blasco
There are few atopic dermatitis (AD) incidence cohort studies in young adults, the etiology of this disease remains obscure, and AD risk factors in adults are not well understood. The objective of this study was to estimate AD ten-year incidence and prevalence in a cohort of adolescent aged 14-16 at inception in Castellon province in Valencia Region, Spain and describe related risk factors. From 2002 to 2012, a population-based prospective cohort study was carried out. Questionnaires from the International Study of Asthma and Allergies in Childhood (ISAAC) were used with an additional questionnaire for related factors completed by participants and their parents, respectively, in 2002. In 2012 the same questionnaires were completed by the participants' through a telephone interview, and incidence and prevalence of AD were estimated. Directed acyclic graphs, Poisson regression and inverse probability weighted regression adjustment were used. The participation rate was 79.5% (1435/1805) with AD lifetime prevalence of 34.9% and AD incidence of 13.5 per 1000 person years. Females presented higher prevalence and incidence than males. After adjustment significant risk factors were being female, history of asthma or allergic rhinitis, family history of AD, history of respiratory infections, history of bronchitis, history of pneumonia, history of sinusitis, and birthplace outside Castellon province. The highest AD population attributable risks were female, 30.3%, and history of respiratory infections 15.3%. Differences with AD childhood risk factors were found. AD incidence in our cohort was high and several risks factors were related to AD.

18 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JGJaume Galceran
Jaume Galceran
AAAlberto Ameijide
Alberto Ameijide
NJNOURA JEGHALEF
NOURA JEGHALEF
AGANTONIA SÁNCHEZ GIL
ANTONIA SÁNCHEZ GIL
MGMarcela Guevara
Marcela Guevara
O(On Behalf Of The Spanish Network Of Cancer Registries (Redecan)
On Behalf Of The Spanish Network Of Cancer Registries (Redecan)
Background: Childhood cancer survivors have a higher risk of developing malignancies later in life compared with individuals of similar age in the general population. In Spain, population-based evidence on second malignant neoplasms (SMNs) is limited. This study aimed to estimate survival following childhood cancer diagnosis and to assess the risk of SMNs in Spain. Methods: This population-based registry study used data from 12 cancer registries within the Spanish Network of Cancer Registries (REDECAN). All malignancies of sites and non-malignant central nervous system (CNS) tumors diagnosed before age 15 were included. Age-standardized incidence rates (ASIRw) for 2015–2019 were calculated. Five- and 10-year age-adjusted observed survival rates for 1990–1999 and 2000–2009 were estimated. SMN risk was assessed using standardized incidence ratios (SIRs) and excess absolute risks (EARs). Results: The ASIRw for 2015–2019 was 181.3 per million child-years. Ten-year survival increased from 71.3% in 1990–1999 to 75.5% in 2000–2009. The overall risk of developing an SMN was significantly elevated (SIR = 5.67) at 20 years. Conclusions: Although survival for childhood cancer in Spain was around 75% in 2000–2009, childhood cancer survivors remain at substantially increased risk of SMNs for at least two decades. Efforts to reduce treatment-related toxicity while maintaining survival gains are essential.

21 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JGJaume Galceran
Jaume Galceran
AAAlberto Ameijide
Alberto Ameijide
NJNOURA JEGHALEF
NOURA JEGHALEF
AGANTONIA SÁNCHEZ GIL
ANTONIA SÁNCHEZ GIL
MGMarcela Guevara
Marcela Guevara
MCMarià Carulla
Marià Carulla
Background: Childhood cancer survivors are more likely to develop cancer in adulthood than people of similar age in the general population. In Spain, there are no popula-tion-based studies on the risk of developing second cancers in people diagnosed with childhood cancer. The main objective of this study was to present recent survival rates fol-lowing a childhood cancer diagnosis in Spain and to investigate the risk of second malig-nant neoplasms (SMNs) in people diagnosed with childhood cancer between 1990 and 2009. Methods: This population-based registry study, devised by the Spanish Network of Cancer Registries (REDECAN), collected data on all malignancies and non-malignant neoplasms of the CNS diagnosed before age 15 years in populations covered by 12 cancer registries of Spain. Age-standardised incidence rates (ASIRw) for the period 2015–19 were calculated per million childhood-years. Five-year and 10-year age-adjusted observed sur-vival rates, for the periods 1990-1999 and 2000–2009 were estimated. The risk of develop-ing SMNs was calculated using standardized incidence ratio (SIR), excess absolute risk (EAR). Age-specific incidence rates of SMN were also calculated. Results: During the pe-riod 2015-2019, the ASIRw was 181.3 per million child-years. The 10-year childhood sur-vival rate for both sexes combined increased from 71.3% to 75.5% between the 1990s and the 2000s. The relative risk of a SMN in people with a first childhood cancer diagnosed between 1990 and 2009 was 5.67 at 20 years after the diagnosis of the first cancer. Conclu-sion: In the 2000s, the 10-year survival rate for childhood cancer in Spain was around 75%, but survivors faced a high risk of developing a second cancer for at least 20 years af-ter their initial diagnosis. Efforts to reduce treatment-related toxicity are essential to miti-gate this long-term risk without compromising survival outcomes.

10 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RVRicardo José Vaamonde-Martín
Ricardo José Vaamonde-Martín
MBMónica Ballesta-Ruiz
Mónica Ballesta-Ruiz
AGANTONIA SÁNCHEZ GIL
ANTONIA SÁNCHEZ GIL
ACAna M. Corbalán-Fernández
Ana M. Corbalán-Fernández
GAGemma Alonso-Sánchez
Gemma Alonso-Sánchez
MCMaría-Dolores Chirlaque-López
María-Dolores Chirlaque-López
Background: Testicular cancer (TC) incidence has risen globally, yet population-based net survival and flexible parametric modeling across histological subtypes in Spain remain insufficiently characterized. Methods: Incident TC cases (1993–2017) were obtained from the Spanish Network of Cancer Registries (REDECAN). Age-standardized incidence rates (ASIR, 2013 European standard) and temporal trends (Joinpoint regression APC) were analyzed by age and histology, including seminomatous germ cell tumors (SGCTs), nonseminomatous germ cell tumors (NSGCTs), and others. Five-year overall survival (OS, Kaplan-Meier) and net survival (NS, Pohar-Perme, ICSS-3 standardized) for 2000–2017 were evaluated. Multivariable flexible parametric models estimated excess hazard ratio (EHR) of mortality. Results: A total of 5,582 cases were analyzed. ASIR increased from 2.31 per 100,000 in 1993–2000 to 5.08 in 2010–2017 (APC=4.6, 95%CI: 4.1; 5.3). Five-year OS and NS reached 94.3% and 95.9% in 2009–2017, respectively. SGCTs demonstrated superior 5-year NS (97.1%) compared to NSGCTs (91.6%) and others (87.8%). Multivariable flexible models revealed significantly higher excess mortality for age ≥40 years (EHR=3.28, 95%CI: 1.95; 5.52 vs 15–24 years), NSGCTs (EHR=4.20, 95%CI: 2.79; 6.30 vs SGCTs), and 'Others' (EHR=5.77), while survival improved in 2009–2017 (EHR=0.70, 95%CI: 0.51; 0.96). Conclusions: TC incidence in Spain more than doubled over 25 years. Survival is generally excellent but exhibits marked disparities by histology and age, emphasizing the need for age-tailored clinical management.